Morgan Stanley’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Morgan Stanley’s Portfolio CRXT Stock Details CRXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6,957	Closed	-$3K	–	8149
2022 Q2	$3K	Buy	+6,957	New	+$4.87K	﹤0.01%	7561
2022 Q1	–	Sell	-2	Closed	–	–	8306
2021 Q4	$0	Buy	+2	New	+$9	﹤0.01%	8306

Other funds holding CRXT

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Morgan Stanley's CRXT Position: Q3 2022 in Review

Morgan Stanley sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 6,957 shares — an estimated $3K sold.

Morgan Stanley first reported a position in CRXT in Q4 2021 and held it in 2 quarters. The position peaked at $3K in Q2 2022. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

Morgan Stanley reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Morgan Stanley sold 6,957 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $3K.
Morgan Stanley first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
Morgan Stanley's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $3K in Q2 2022.
2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Morgan Stanley's 13F filing for Q3 2022, filed 14 Nov 2022.